Head/Neck Cancer News

An AI model achieved higher accuracy than three cytopathologists for determining malignancy in a large dataset of image patches of thyroid fine-needle aspiration whole-slide images, according to a study published in Thyroid.

Individuals with laryngeal cancer who stop smoking in the 2- to 4-week window between diagnosis and their first treatment can significantly improve their response to therapy, survival rates and quality of life.

People with type 2 diabetes who use a GLP-1 receptor agonist have a lower risk for 10 types of obesity-associated cancer compared with those who use insulin, according to data published in JAMA Network Open.

CHICAGO — HPV vaccination rates for children and young adults increased substantially during the 2010s regardless of gender, race or ethnicity, according to findings presented at ASCO Annual Meeting.

A randomized phase 3 trial designed to evaluate xevinapant with chemoradiotherapy as treatment for certain patients with head and neck cancers has been discontinued due to likely lack of benefit, according to the agent’s manufacturer.

Individuals with therapy-refractory cancer who received waivers to participate in a clinical trial for off-label targeted therapies achieved similar clinical benefits as those who took part in the study without an exception.

A phase 3 clinical trial will evaluate a nerve fluorescing product designed to illuminate nerves during head and neck tumor removal, allowing surgeons to locate them more easily.

The FDA granted accelerated approval to repotrectinib for the treatment of adults and children 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase gene fusion.

CHICAGO — Glucagon-like peptide-1 receptor agonists lowered the risk for obesity-related cancers compared with bariatric surgery among individuals with a BMI of at least 35, according to data presented at ASCO Annual Meeting.

The FDA granted accelerated approval to selpercatinib for the treatment of certain pediatric patients with metastatic or advanced solid tumors harboring RET alterations.